Physician profile
Gary Fredericksen
NPI 1629035225
$1,800.06
in general payments reported to CMS, 2019-2025
24 companies · $636 in 2025
The $636 reported for 2025 was more than what 83% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $75.22 · 2021: $85.20 · 2022: $104 · 2023: $147 · 2024: $409 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $242.43 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $232.31 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $222.68 | 2019-2025 | Rocklatan, Clareon, Tryptyr |
| Bausch & Lomb Americas INC. | $178.22 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Johnson & Johnson Vision Care, INC. | $149.46 | 2019-2022 | |
| Allergan, INC. | $111.40 | 2019-2022 | |
| Abbvie INC. | $111.03 | 2024-2025 | |
| Oyster Point Pharma, INC. | $68.51 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $60.55 | 2025 | Oxervate |
| Amgen INC. | $58.86 | 2024-2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $52.22 | 2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $51.00 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $36.40 | 2024 | Acthar |
| Glaukos Corporation | $31.12 | 2025 | Idosetr |
| Shire North American Group INC | $30.36 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $24.33 | 2025 | Iyuzeh |
| Rxsight INC | $23.97 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Harrow Eye, LLC | $20.39 | 2024 | Vevye |
| Kala Pharmaceuticals, INC. | $19.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.69 | 2023 | |
| Rayner Intraocular Lenses Limited | $14.92 | 2025 | Omidria |
| Horizon Therapeutics Plc | $14.43 | 2021 | |
| Aerie Pharmaceuticals, INC. | $13.65 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Fredericksen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.